Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Tornatore L, et al. Among authors: kaiser mf. Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. Br J Haematol. 2019. PMID: 30255568 Free article. No abstract available.
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
Brioli A, Boyd KD, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Brioli A, et al. Among authors: kaiser mf. Br J Haematol. 2013 Apr;161(2):291-4. doi: 10.1111/bjh.12218. Epub 2013 Jan 29. Br J Haematol. 2013. PMID: 23356460 Free article. Clinical Trial. No abstract available.
Improved risk stratification in myeloma using a microRNA-based classifier.
Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. Wu P, et al. Br J Haematol. 2013 Aug;162(3):348-59. doi: 10.1111/bjh.12394. Epub 2013 May 30. Br J Haematol. 2013. PMID: 23718138 Free article.
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation.
Parzych K, Saavedra-García P, Valbuena GN, Al-Sadah HA, Robinson ME, Penfold L, Kuzeva DM, Ruiz-Tellez A, Loaiza S, Holzmann V, Caputo V, Johnson DC, Kaiser MF, Karadimitris A, Lam EW, Chevet E, Feldhahn N, Keun HC, Auner HW. Parzych K, et al. Among authors: kaiser mf. Oncogene. 2019 Apr;38(17):3216-3231. doi: 10.1038/s41388-018-0651-z. Epub 2019 Jan 9. Oncogene. 2019. PMID: 30626938 Free PMC article.
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.
Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Tornatore L, et al. Among authors: kaiser mf. Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019. Toxicol Rep. 2019. PMID: 31080744 Free PMC article.
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.
Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, Jenner M, Henshaw S, Hall R, Sive J, Stern S, Streetly M, Bygrave C, Soutar R, Rabin N, Jackson GH; United Kingdom Myeloma Forum. Cook G, et al. Br J Haematol. 2020 Jul;190(2):e83-e86. doi: 10.1111/bjh.16874. Epub 2020 Jun 10. Br J Haematol. 2020. PMID: 32438482 Free PMC article. No abstract available.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, Jenner M, Cook G, Drayson M, Owen R, Gregory W, Morgan G, Jackson G, Kaiser M. Bygrave C, et al. Br J Haematol. 2021 May;193(3):551-555. doi: 10.1111/bjh.16793. Epub 2020 Jun 10. Br J Haematol. 2021. PMID: 32524584 Free PMC article. Clinical Trial.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Jackson GH, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Wilson J, Taylor C, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Drayson MT, Kaiser MF, Owen RG, Gregory WM, Davies FE, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group. Jackson GH, et al. Among authors: kaiser mf. Br J Haematol. 2021 Mar;192(5):853-868. doi: 10.1111/bjh.16945. Epub 2020 Jul 12. Br J Haematol. 2021. PMID: 32656799 Free article. Clinical Trial.
171 results